Latest News and Press Releases

"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"

Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.

Hawai’i Cancer Care and American Oncology Network Open New Kahului Clinic

This Giving Tuesday and throughout the holiday season, Albertans are asked to give the gift of time to loved ones facing a cancer journey.

EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastomaData presented at 2025 SNO conference by lead investigator Paris, France – 2 DECEMBER...

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...

These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical...

Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

Boston, Nov. 27, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “AI in Neurology: Global Markets” is estimated to increase from $705.6 million in 2025 to $2.5 billion by...